Quick Tips

What are the commonly used systemic agents?

Learn more on this topic: Optimizing Outcomes for Patients With Soft-Tissue Sarcomas Through the Multidisciplinary Medical Oncology/Radiation/Surgical Team Approach

Leah Clark, MS, ARNP, on soft-tissue sarcomas: a multidisciplinary team approach.

What are key strategies for managing AML in older adults?

Learn more on this topic: Managing the Continuum of Myeloid Malignancies (CML, MPN, MDS, and AML)

Jean Ridgeway, DNP, APN, NP-C, AOCN, and Andrew Artz, MD, on managing myeloid malignancies.

What are the indications of a germline predisposition in a patient with a known or suspected myeloid malignancy?

Learn more on this topic: Managing the Continuum of Myeloid Malignancies (CML, MPN, MDS, and AML)

Jean Ridgeway, DNP, APN, NP-C, AOCN, and Andrew Artz, MD, on managing myeloid malignancies.

How do I select patients for treatment with extended adjuvant therapies such as neratinib?

Learn more on this topic: Advances in Extended Adjuvant HER2-Positive Early Breast Cancer

G. Thomas Budd, MD, on advances in extended adjuvant HER2+ early breast cancer.

What are the mechanisms of action for novel extended adjuvant therapies?

Learn more on this topic: Advances in Extended Adjuvant HER2-Positive Early Breast Cancer

G. Thomas Budd, MD, on advances in extended adjuvant HER2+ early breast cancer.

What are the procedures to identify and overcome resistance to targeted treatments?

Learn more on this topic: Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer

Beth Eaby-Sandy, MSN, CRNP, OCN, on advances in targeted treatments for non–small cell lung cancer.

What are the tools used to predict response to targeted treatments for colorectal cancer?

Learn more on this topic: Hereditary Aspects of Colorectal Cancer

Michael Hall, MD, on hereditary colorectal cancer.

Why do I need to use loperamide when managing diarrhea in patients treated with neratinib?

Learn more on this topic: Advances in Extended Adjuvant HER2-Positive Early Breast Cancer

Lee S. Schwartzberg, MD, of West Cancer Center, on advances in extended adjuvant therapy for HER2+ breast cancer.

What are the screening tests for Lynch syndrome, and how do you interpret the results?

Learn more on this topic: Hereditary Aspects of Colorectal Cancer

Heather Hampel, MS, LGC, and Michael Hall, MD, on hereditary colorectal cancer.

How do you identify patients at risk for Lynch syndrome?

Learn more on this topic: Hereditary Aspects of Colorectal Cancer

Heather Hampel, MS, LGC, on hereditary colorectal cancer.

How are patients selected for CAR-T therapy?

Learn more on this topic: New Drug Updates in Hematologic Malignancies: CAR T Cells, Targeted Therapeutics, and Other Agents

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on hematologic cancers: drug updates.

What are the most recently approved medications for managing hematologic malignancies?

Learn more on this topic: New Drug Updates in Hematologic Malignancies: CAR T Cells, Targeted Therapeutics, and Other Agents

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on hematologic cancers: drug updates.

For which immune-related adverse events is it important to consult specialty services early?

Learn more on this topic: Managing Side Effects of Cancer Patients Treated With Immunotherapy

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura Zitella, MS, RN, ACNP-BC, AOCN, on managing immunotherapy side effects.

How do you educate patients about what to expect in terms of how their disease will respond to immunotherapy?

Learn more on this topic: Managing Side Effects of Cancer Patients Treated With Immunotherapy

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura Zitella, MS, RN, ACNP-BC, AOCN, on managing immunotherapy side effects.

What do you tell patients about the side effects they may experience?

Learn more on this topic: Managing Side Effects of Cancer Patients Treated With Immunotherapy

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura Zitella, MS, RN, ACNP-BC, AOCN, on managing immunotherapy side effects.

What are the elements of a multidisciplinary approach to treating patients with soft-tissue sarcomas?

Learn more on this topic: Optimizing Outcomes for Patients With Soft-Tissue Sarcomas Through the Multidisciplinary Medical Oncology/Radiation/Surgical Team Approach

David Johnson, PA-C, on soft-tissue sarcomas: a multidisciplinary team approach.

What is the clinical relevance of FLT3 and IDH2 mutations in AML?

Learn more on this topic: A Deeper Dive into Advanced and Future Directions in Treating Patients with Acute Myeloid Leukemia

Sandy Kurtin, PhDc, ANP-C, AOCN, on treating patients with AML.

What is the best strategy for managing minimal residual disease?

Learn more on this topic: Risk Stratification in Multiple Myeloma: Putting the Pieces Together

Hans C. Lee, MD, on risk stratification in multiple myeloma.

What information will help patients recognize immune-related toxicities?

Learn more on this topic: Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

Emily Lemke, DNP, AGPCNP-BC, AOCNP, on managing patients with urothelial carcinomas of the bladder.

What are the signs and symptoms of serious adverse effects linked with newly approved solid tumor drugs?

Learn more on this topic: New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

Edward Li, PharmD, MPH, BCOP, on solid tumors: new drug approvals.

What data from clinical trials do the FDA consider when approving new drugs for solid tumors?

Learn more on this topic: New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

Edward Li, PharmD, MPH, BCOP, on solid tumors: new drug approvals.

What type of patients are the best candidates for adjuvant radiation therapy?

Learn more on this topic: Optimizing Outcomes for Patients With Soft-Tissue Sarcomas Through the Multidisciplinary Medical Oncology/Radiation/Surgical Team Approach

Arash Naghavi, MD, on soft-tissue sarcomas: a multidisciplinary team approach.

What is the best way to explain to patients the role of immunotherapies in treating their disease?

Learn more on this topic: Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

Amishi Shah, MD, on managing patients with urothelial carcinomas of the bladder.

What are the differences between immunotherapeutic and chemotherapeutic agents?

Learn more on this topic: Advances in the Management of Patients with Urothelial Carcinomas of the Bladder

Amishi Shah, MD, on managing patients with urothelial carcinomas of the bladder.

What are the best ways to manage side effects associated with EGFR and ALK inhibitors?

Learn more on this topic: Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer

Beth Eaby-Sandy, MSN, CRNP, OCN, and Elizabeth Waxman, RN, MSN, AOCN, ANP-BC, on advances in targeted treatments for non–small cell lung cancer.

What side effects should practitioners be aware of with AML?

Learn more on this topic: A Deeper Dive into Advanced and Future Directions in Treating Patients with Acute Myeloid Leukemia

Gabrielle Zecha, PA-C, MHA, on treating patients with acute myeloid leukemia.

How do you manage toxicities of immunotherapeutic agents?

Mollie Reed, MSN, RN, ACNP-BC, of Tennessee Oncology, on treating patients with immunotherapy.

How do I distinguish between prescribed drugs, parent biologics, and competing biosimilars?

Related article in JADPRO Vol 8, No 7, Nov/Dec 2017 issue

How does a biosimilar compare to its reference product?

Related article in JADPRO Vol 8, No 7, Nov/Dec 2017 issue

What are the biosimilars with current or pending approval from the FDA?

Related article in JADPRO Vol 8, No 7, Nov/Dec 2017 issue

Is it important for me to be involved in post-market studies of biosimilars?

Related article in JADPRO Vol 8, No 7, Nov/Dec 2017 issue

How do you educate patients about the timing of early and latent side effects?

Learn more on this topic: Overview of Immunotherapy

What cancers are most likely to respond to immunotherapy?

Learn more on this topic: Overview of Immunotherapy

How do responses to immune checkpoint inhibitors differ from responses to chemotherapy?

Learn more on this topic: Overview of Immunotherapy

What are the mechanisms of action and adverse effects of these agents?

Learn more on this topic: Overview of Immunotherapy

Why is pseudo-progression an important issue in patients on immune checkpoint inhibitors?

Learn more on this topic: Overview of Immunotherapy

When should you image patients to assess response to immunotherapy?

Learn more on this topic: Overview of Immunotherapy

Is programmed cell death ligand 1 (PD-L1) testing necessary?

Learn more on this topic: Overview of Immunotherapy

What are the mechanisms of action of targeted treatments and immunotherapies?

Learn more on this topic: An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

What is the current thinking on the diagnosis and treatment of patients with squamous cell NSCLC?

Learn more on this topic: An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

What are the genetic variants in NSCLC, and how are they used to select treatment?

Learn more on this topic: An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

How do you interpret a patient’s therapeutic response to treatment?

Learn more on this topic: An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

How do you identify and manage adverse events?

Learn more on this topic: An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC

What are some of the emerging therapies and their mechanisms of action?

Filmed at the JADPRO Regional Lecture Series on hematologic malignancies.

What are some of the emerging therapies and how do you select and sequence treatments?

How do you select and sequence treatments in the upfront and relapsed/refractory settings?

Filmed at the JADPRO Regional Lecture Series on hematologic malignancies.

What should you be aware of when monitoring for toxicities linked with newer agents?

Filmed at the JADPRO Regional Lecture Series on hematologic malignancies.

What should you be aware of when monitoring for toxicities linked with newer agents?

Filmed at the JADPRO Regional Lecture Series on hematologic malignancies.

What are the best ways to help patients adhere to oral therapies?

Filmed at the JADPRO Regional Lecture Series on hematologic malignancies.

What is the role of the advanced practitioner on the cancer care team in oral adherence?

Filmed at the JADPRO Regional Lecture Series on hematologic malignancies.

What should you be aware of when monitoring for toxicities linked with newer agents?

Filmed at the JADPRO Regional Lecture Series on hematologic malignancies.

What are some of the emerging therapies and how do you select and sequence treatments?

Filmed at the JADPRO Regional Lecture Series on hematologic malignancies.

What are some of the emerging therapies and their mechanisms of action?

Filmed at the JADPRO Regional Lecture Series on hematologic malignancies.

What should you be aware of when monitoring for toxicities linked with newer agents?

Filmed at the JADPRO Regional Lecture Series on hematologic malignancies.

How do you optimize patient outcomes when adverse events occur?

Filmed at the JADPRO Regional Lecture Series on hematologic malignancies.